Table 5.
Rates of complications in the endoscopic therapy+nonselective β-blockers and covered transjugular intrahepatic portosystemic shunt groups
| Complications |
10 mmHg ≤ HVPG < 16 mmHg (n = 70)
|
HVPG ≥ 16 mmHg (n = 114)
|
||||||
|
Total
|
Endoscopic therapy + NSBBs (n = 46)
|
Covered TIPS (n = 24)
|
P value
|
Total
|
Endoscopic therapy + NSBBs (n = 56)
|
Covered TIPS (n = 58)
|
P value
|
|
| OHE during follow-up (yes/no) | 2/68 | 0/46 | 2/22 | 0.11 | 10/104 | 3/53 | 9/49 | 0.049 |
| Jaundice during follow-up (yes/no) | 22/48 | 14/32 | 8/16 | 0.79 | 46/68 | 17/39 | 29/29 | 0.04 |
| Ascites during follow-up (yes/no) | 29/41 | 18/28 | 11/13 | 0.62 | 75/39 | 38/18 | 37/21 | 0.70 |
| Hypercreatinemia during follow-up(yes/no) | 10/60 | 5/41 | 5/19 | 0.29 | 13/101 | 6/50 | 7/51 | 1.00 |
| Hyponatremia during follow-up (yes/no) | 11/59 | 9/37 | 2/22 | 0.31 | 8/106 | 4/52 | 4/54 | 1.00 |
| OHE in 1 year (yes/no) | 8/62 | 3/43 | 5/19 | 0.09 | 22/92 | 9/47 | 13/45 | 0.48 |
| Jaundice in 1 year(yes/no) | 11/59 | 5/41 | 6/18 | 0.17 | 29/85 | 8/48 | 21/37 | 0.01 |
| Ascites in 1 year (yes/no) | 34/36 | 23/23 | 11/13 | 0.80 | 74/40 | 35/21 | 39/19 | 0.70 |
| Hypercreatinemia in 1 year (yes/no) | 5/65 | 2/44 | 3/21 | 0.33 | 4/110 | 3/53 | 1/57 | 0.36 |
| Hyponatremia in 1 year (yes/no) | 7/63 | 5/41 | 2/22 | 1.00 | 20/94 | 12/44 | 8/50 | 0.33 |
HVPG: Hepatic venous pressure gradient; NSBBs: Non-selective β-blockers; TIPS: Transjugular intrahepatic portosystemic shunts; OHE: Overt hepatic encephalopathy.